sinc
fire
et
al
discov
rna
interfer
rnai
mediat
long
doublestrand
rna
dsrna
caenorhabd
elegan
subsequ
demonstr
rnai
mediat
small
interf
rna
sirna
oper
mammalian
cell
rnai
becom
major
subject
interest
tool
biolog
research
also
import
therapeut
approach
generel
diseas
sirna
short
doublestrand
rna
contain
nucleic
acid
duplex
region
abl
inhibit
gene
express
specif
protein
mechan
call
rna
interfer
occur
two
differ
phase
explain
fig
thu
abil
sirna
potent
revers
silenc
gene
vivo
made
sirna
particularli
wellsuit
new
class
drug
interfer
diseasecaus
diseasepromot
gene
specif
potenc
versatil
major
advantag
rnai
therapeut
compar
small
molecul
drug
sirna
advantag
sequenc
highli
specif
inhibit
target
interest
gene
molecular
class
target
unlik
therapeut
protein
sirna
synthesi
straightforward
requir
cellular
express
system
complex
protein
purif
refold
scheme
final
compar
geneantisens
therapi
advantag
sirna
includ
robust
potenc
potent
gene
silenc
specif
inhibit
cytoplasm
site
action
low
risk
toxic
effect
howev
despit
potenti
clinic
use
sirna
applic
treatment
chronic
sever
diseas
limit
sever
factor
difficult
cellular
uptak
low
rate
cell
transfect
rapid
degrad
endogen
enzym
result
short
halflif
neg
charg
prevent
cross
cell
membran
insuffici
bioavail
therefor
vivo
effect
sirna
depend
deliveri
target
tissu
intracellular
compart
cell
type
interest
within
target
tissu
first
requir
common
class
drug
wherea
second
one
common
drug
intracellular
target
context
sever
synthet
nonvir
carrier
propos
last
year
quickli
gain
popular
safe
effici
vector
deliv
sirna
target
organ
along
develop
mani
innov
technolog
effect
drug
deliveri
address
issu
inject
sirna
includ
use
liposom
polym
nanoparticl
develop
altern
rout
administr
investig
extens
increas
number
studi
propos
differ
approach
local
deliveri
therapeut
sirna
consid
system
administr
sirna
face
import
obstacl
includ
low
bioavail
system
toxic
rapid
excret
ineffici
target
affect
organ
cell
type
local
administr
becom
attract
effect
rout
allow
use
lower
dose
reduc
side
effect
given
increas
number
studi
propos
new
optimum
sirna
deliveri
strategi
efficaci
silenc
diseas
gene
present
review
provid
overview
import
recent
develop
deliv
sirna
via
local
administr
rout
discuss
main
diseas
target
local
deliveri
sirna
specif
tissu
organ
includ
skin
lung
eye
nervou
system
digest
system
vagina
widespread
use
rnai
therapeut
approach
gene
therapi
depend
deliveri
nucleic
acid
molecul
cell
thu
requir
develop
clinic
suitabl
safe
effect
drug
deliveri
system
gener
ideal
carrier
local
deliveri
sirna
meet
sever
criteria
first
sirna
carrier
overcom
inher
barrier
impos
administr
rout
exampl
cutan
sirna
deliveri
stratum
corneum
outermost
layer
skin
repres
primari
impedi
drug
skin
penetr
especi
drug
high
molecular
weight
complex
structur
sirna
anatomi
morpholog
lung
epithelium
main
limit
effici
pulmonari
sirna
deliveri
addit
physic
barrier
ocular
sirna
therapi
tear
film
cover
ocular
surfac
corneal
conjunctiv
epitheli
cell
metabol
barrier
may
degrad
reduc
efficaci
drug
final
effect
formul
aim
deliv
gene
central
nervou
system
cn
must
cross
barrier
access
endogen
receptor
express
within
membran
system
carrier
bind
condens
sirna
provid
protect
degrad
nake
sirna
suscept
enzymat
degrad
bodi
addit
carrier
deliv
sirna
specif
target
cell
contact
cell
facilit
cellular
uptak
sirna
way
carrier
circumv
inabl
nake
sirna
passiv
diffus
cellular
membran
due
rel
larg
molecular
weight
strong
anion
charg
insid
cell
carrier
escap
endosom
traffick
lysosom
reach
cell
cytoplasm
without
metabol
final
carrier
releas
sirna
proper
function
effici
silenc
gene
viral
vector
appli
sirna
deliveri
throughout
evolut
develop
strategi
allow
entri
genom
host
cell
viral
vector
adenovirus
retrovirus
high
transfect
effici
also
present
cytotox
oncogen
immunogen
altern
nonvir
vector
polyplex
lipoplex
peptid
proteinbas
system
sirna
shown
promis
tool
gene
deliveri
mainli
enabl
incorpor
ligand
target
specif
cell
type
reason
safe
fig
typic
cation
liposom
cation
lipid
n
n
n
ntrimethylammonium
propan
methylsulf
dotap
n
n
ndimethyl
ammonium
bromid
dmrie
use
form
complex
lipoplex
spontan
electrostat
interact
posit
charg
amin
head
group
cation
lipid
phosphat
group
nucleic
acid
compon
therebi
deliv
sirna
differ
cell
type
lipoplex
great
similar
cell
membran
suggest
drug
deliveri
occur
membran
fusion
although
lipoplex
gener
good
transfect
effici
easi
prepar
poor
stabil
poor
reproduc
consid
sirna
deliveri
system
base
cation
polym
receiv
attent
due
biocompat
eas
product
versatil
mani
physicochem
modif
made
obtain
intend
effect
special
interest
given
cation
polym
abl
form
nanoscal
complex
polyplex
sirna
base
electrostat
interact
posit
charg
neg
charg
sirna
condens
larg
structur
gene
neutral
strongli
neg
charg
provid
good
transfect
rate
one
major
concern
use
cation
polym
deliveri
system
sirna
toxic
due
cation
nondegrad
characterist
nondegrad
consid
main
reason
toxic
cation
polym
even
similar
silenc
activ
achiev
biodegrad
nonbiodegrad
polym
find
encourag
use
biodegrad
biocompat
polymerbas
system
sirna
deliveri
use
chitosan
cs
base
system
poli
lacticcoglycol
acid
plga
nanoparticl
peptid
transduct
domain
ptd
cellpenetr
peptid
cpp
attract
drug
vector
due
abil
transloc
micro
macromolecul
across
cell
membran
vector
defin
small
posit
charg
peptid
contain
amino
acid
abl
interact
nucleic
acid
sirna
electrostat
interact
induc
intern
differ
endocyt
mechan
arginin
lysin
residu
usual
present
structur
provid
cation
charg
membran
permeabl
also
ad
previous
develop
sirna
vector
optim
effect
tabl
describ
differ
polym
lipid
peptid
proteinbas
system
develop
deliv
sirna
local
administr
rout
shown
tabl
achiev
desir
gene
silenc
innov
techniqu
sirna
deliveri
local
administr
propos
progress
pharmaceut
formul
provid
promis
strategi
overcom
barrier
exist
tissu
extracellular
cellular
level
addit
elucid
main
factor
contribut
overcom
common
specif
obstacl
local
administr
sirna
allow
ration
model
exist
deliveri
system
order
optim
effect
howev
number
challeng
still
confront
translat
sirna
therapi
laboratori
clinic
depend
upon
develop
system
capabl
provid
bioactiv
sirna
specif
site
conveni
dose
scheme
favor
toxic
profil
addit
nonvir
vector
describ
previous
physic
deliveri
method
merit
mention
fig
may
includ
hydrodynam
method
gene
gun
ultrasound
electropor
iontophoresi
last
two
commonli
use
review
discuss
local
sirna
deliveri
via
physic
method
electropor
far
commonli
use
methodolog
techniqu
consist
improv
cell
membran
permeabl
appli
extern
electr
field
method
act
revers
destabil
plasma
membran
enabl
easier
permeat
drug
genet
materi
effect
result
obtain
pore
adequ
size
remain
open
suffici
amount
time
destroy
membran
integr
mani
advantag
use
techniqu
compar
deliveri
vector
gene
therapi
transfect
efficaci
primari
cell
high
ii
reduc
safeti
concern
iii
method
easi
appli
iv
littl
influenc
cell
line
effici
iontophoresi
anoth
noninvas
method
small
electr
current
use
enhanc
penetr
ioniz
drug
method
drug
appli
surfac
electrod
charg
opposit
charg
electrod
place
anoth
part
bodi
establish
current
flow
among
notabl
advantag
approach
eas
applic
minim
system
side
effect
increas
local
permeabl
make
iontophoresi
common
techniqu
employ
skin
ocular
drug
deliveri
tabl
ii
describ
repres
studi
propos
use
differ
physic
method
strategi
improv
local
sirna
deliveri
specif
tissu
organ
skin
eye
nervou
digest
system
increas
express
inflammatori
skin
diseas
report
human
anim
block
express
sirna
influenc
cell
responsespecif
antigen
anim
model
allerg
diseas
therapi
sirna
dendrit
cell
treatment
contact
hypersensit
atop
dermat
success
reduc
innat
adapt
immun
respons
bodi
local
region
lymph
node
addit
creamemuls
formul
use
conveni
econom
method
drug
deliveri
contrast
allerg
skin
episod
psoriasi
chronic
inflammatori
diseas
character
demarc
erythemat
scali
plaqu
abnorm
acceler
prolifer
keratinocyt
lead
epiderm
hyperplasia
tumor
necrosi
factor
alpha
proinflammatori
cytokin
upregul
psoriat
lesion
import
molecular
target
treatment
skin
disord
reduct
level
express
proinflammatori
cytokin
lead
phenotyp
improv
reduc
epiderm
thick
normal
skin
morpholog
psoriasi
anim
model
given
known
play
pivot
role
psoriasi
johansen
et
al
identifi
potenti
target
treatment
psoriasi
mapk
mapkactiv
protein
kinas
posttranscript
regul
express
proinflammatori
cytokin
research
group
publish
two
report
demonstr
role
mitogenand
stressactiv
protein
kinas
pathogenesi
psoriasi
suggest
signal
pathway
might
constitut
potenti
therapeut
target
diseas
pachyonychia
congenita
domin
neg
genet
diseas
skin
caus
mutat
gene
encod
keratin
diseas
character
thicken
nail
palmoplantar
hyperkeratosi
leukokeratosi
pain
keratoderma
blister
sole
feet
frequent
mutat
gene
due
locat
lesion
noninvas
topic
treatment
great
advantag
rnaibas
therapeut
technolog
select
elimin
function
mutant
allel
provid
effect
treatment
patholog
notabl
among
ongo
clinic
trial
use
sirna
two
involv
treatment
pachyonychia
congenita
one
treatment
use
specif
sirna
gene
studi
first
evalu
use
sirna
human
skin
aim
assess
safeti
toler
intrales
inject
callus
patient
pachyonychia
congenita
vari
volum
concentr
sirna
sirna
known
efficaci
sirna
treatment
assess
clinic
examin
patient
report
experi
quantifi
distinguish
mutant
keratin
mrna
alopecia
areata
autoimmun
diseas
affect
hair
follicl
result
hair
loss
examin
around
hair
follicl
reveal
infiltr
lymphocyt
along
intrafollicular
infiltr
suggest
import
role
cell
occurr
alopec
lesion
subcutan
inject
cation
gelatin
conjug
tbox
sirna
gene
play
import
role
cell
differenti
function
promot
reestablish
hair
shaft
elong
confirm
import
mediat
wound
repres
substanti
biomed
burden
among
varieti
diseas
suscept
local
express
gene
modul
strateg
rnai
mitogen
activ
protein
lamin
ac
select
potenti
molecular
target
ubiquit
natur
high
level
express
cutan
wound
topic
applic
agarosematrixbas
system
deliv
sirnaliposom
transfect
complex
effect
silenc
local
gene
express
nondelimit
wound
melanoma
cancer
pigment
skin
cell
call
melanocyt
local
epidermalderm
junction
genet
mechan
involv
type
cancer
well
understood
howev
mutat
protein
rapidli
grow
fibrosarcoma
protein
member
famili
serinethreonin
kinas
substitut
valin
glutam
acid
posit
amino
acid
sequenc
increas
activ
also
known
protein
kinas
b
frequent
chang
found
diseas
employ
sirna
specif
target
gene
inhibit
develop
growth
melanoma
although
rheumatoid
arthriti
cutan
diseas
skin
extens
use
administr
rout
drug
treatment
diseas
osteopontin
extracellular
matrix
cytokin
transcrib
activ
lymphocyt
import
therapeut
target
mani
inflammatori
diseas
includ
autoimmun
diseas
rheumatoid
arthriti
character
chronic
inflamm
joint
destruct
therapeut
applic
sirna
target
confirm
observ
suppress
antibodyinduc
develop
rheumatoid
arthriti
symptom
topic
applic
cream
formul
genecream
patent
pend
load
silenc
consid
incid
rate
mortal
lung
cancer
one
common
tumor
worldwid
even
increas
knowledg
genet
molecular
basi
lung
cancer
patient
noncur
tumor
die
less
month
gene
therapi
welltoler
strategi
develop
novel
treatment
concept
base
inhibit
protein
overexpress
tumor
may
import
invas
growth
cell
motil
promis
target
treatment
cancer
wilm
tumor
gene
whose
overexpress
relat
develop
progress
divers
cancer
thu
vivo
silenc
gene
sirna
seem
effect
strategi
treatment
lung
metastas
fibrin
accumul
common
mani
acut
chronic
pulmonari
diseas
express
level
plasminogen
activ
directli
correl
extent
lung
injuryinduc
accumul
collagen
major
molecul
relat
develop
pulmonari
fibrosi
recent
studi
show
intranas
administr
potenti
strategi
prevent
develop
pulmonari
fibrosi
enhanc
surviv
rate
mice
bleomycininduc
lung
injuri
addit
interest
therapeut
approach
may
avoid
system
side
effect
associ
oral
administr
inhibitor
tuberculosi
univers
diseas
caus
infect
mycobacterium
tuberculosi
respons
two
million
death
everi
year
recent
candid
among
inhal
tuberculosi
therapi
sirna
target
host
chemokin
lymphotactin
known
particip
format
tuberculoid
granuloma
treatment
mice
previous
infect
day
mycobacterium
tuberculosi
aerosol
sirna
modul
lung
immunopatholog
one
preval
infect
human
influenza
viru
envelop
viru
orthomyxoviru
famili
influenza
infect
caus
death
per
year
unit
state
exist
vaccin
effect
use
four
drug
approv
treatment
influenza
infect
limit
side
effect
possibl
emerg
resist
virus
thu
develop
effici
influenza
therapi
vaccin
necessari
studi
test
sirna
influenza
viru
found
specif
sirna
inhibit
influenza
viru
product
cell
line
embryon
chicken
egg
sar
diseas
caus
sar
coronaviru
scv
new
diseas
safe
effect
vaccin
exist
yet
though
effort
toward
develop
intensifi
use
rhesu
macaqu
sar
model
li
et
al
intranas
administ
mixtur
two
scvspecif
sirna
duplex
show
outstand
prophylact
therapeut
activ
cell
cultur
administ
prophylact
concomitantli
postexposur
within
period
day
infect
treatment
regimen
show
potent
suppress
scv
toxic
nonhuman
primat
model
rsv
member
pneumovirina
subfamili
pneumoviru
genu
envelop
nonseg
negativestrand
rna
viru
respons
seriou
respiratori
infect
bronchiol
pneumonia
infant
young
children
current
vaccin
prevent
rsv
accept
therapi
ribavirin
seldom
use
due
teratogen
limit
antivir
effect
controversi
clinic
effect
interest
approach
prevent
treatment
diseas
caus
rsv
use
sirna
therapi
administ
intranas
differ
studi
conduct
valid
diseas
target
vivo
use
sirna
phosphoprotein
p
protein
essenti
subunit
viral
rnadepend
rna
polymeras
reduc
pulmonari
rsv
titer
approxim
moreov
applic
sirna
target
gene
balbc
mice
rsv
infect
significantli
attenu
diseas
diminish
lung
inflamm
goblet
cell
hyperplasia
infiltr
inflammatori
cell
compar
control
mice
anoth
promis
sirna
rsv
sirna
direct
mrna
encod
nucleocapsid
n
protein
rsv
protein
import
role
mani
critic
step
viral
replic
cycl
includ
involv
rna
polymeras
function
n
protein
gene
among
conserv
across
variou
circul
rsv
isol
characterist
allow
broadspectrum
activ
nproteintarget
sirna
vivo
studi
use
sirna
molecular
target
therapeut
agent
began
test
anim
show
potent
antivir
effect
administ
intranas
human
de
vincenzo
et
al
conduct
safeti
studi
healthi
volunt
demonstr
intranas
administr
dose
mg
daili
day
welltoler
later
antivir
activ
test
random
doubleblind
placebocontrol
trial
adult
subject
experiment
infect
wildtyp
rsv
studi
demonstr
effect
intranas
inocul
viru
howev
author
suggest
studi
must
conduct
evalu
effici
natur
infect
patient
establish
lower
respiratori
tract
diseas
therefor
random
trial
lung
transplant
patient
natur
infect
rsv
receiv
aerosol
placebo
daili
day
conclud
aerosol
safe
welltoler
associ
reduc
rate
new
progress
bronchiol
obliteran
syndrom
case
compar
placebo
group
common
problem
affect
central
region
choroid
retina
agerel
macular
degener
progress
degener
retin
epithelium
affect
photoreceptor
sever
condit
progress
irrevers
blind
macular
degener
trigger
protein
vascular
endotheli
growth
factor
vegf
promot
blood
vessel
growth
leakag
blood
vessel
induc
diseas
acuiti
pharmaceut
start
first
human
clinic
trial
sirna
patient
suffer
agerel
macular
degener
vegftarget
sirna
bevasiranib
administ
eye
local
intravitr
inject
prevent
overgrowth
new
blood
vessel
preliminari
result
show
doserel
benefit
began
clinic
trial
diabet
macular
edema
shortli
thereaft
sirna
therapeut
produc
first
sirna
target
vegf
receptor
treatment
diseas
singl
intravitr
administr
well
toler
patient
improv
visual
acuiti
occur
subset
subject
howev
berkhout
show
evid
preclin
efficaci
sirna
therapeut
observ
macular
degenerationinduc
mous
model
like
due
nonspecif
side
effect
rather
sequencespecif
gene
knockdown
report
indic
develop
safe
sirnabas
therapi
may
challeng
anticip
reemphas
import
includ
appropri
control
rnai
experi
diabet
retinopathi
lead
caus
blind
current
cure
diseas
result
vascular
abnorm
includ
increas
vascular
permeabl
retin
neurodegener
caus
irrevers
chang
occur
earli
cours
diabet
retinopathi
therefor
prevent
increas
vascular
permeabl
neuron
cell
death
appear
reason
strategi
mitig
complic
associ
diseas
oshitari
et
al
demonstr
abnorm
express
vascular
basement
membran
compon
may
play
role
develop
increas
vascular
permeabl
associ
diabet
retinopathi
moreov
screen
differ
sirna
fibronectin
laminin
collagen
iv
author
demonstr
sirna
strategi
may
use
delay
prevent
excess
vascular
permeabl
angiogenesi
neovascular
caus
sever
ocular
diseas
includ
agerel
macular
degener
herpet
stromal
kerat
central
branch
retina
vein
occlus
trauma
variou
inflammatori
ocular
diseas
diabet
retinopathi
exact
mechan
underli
pathogenesi
ocular
neovascular
well
understood
shown
vegf
directli
involv
new
vascular
possibl
use
sirna
treat
neovascular
demonstr
employ
sirna
vegf
vegf
receptor
therapi
test
clinic
trial
studi
demonstr
topic
deliveri
sirna
direct
vegf
function
effici
suppress
corneal
neovascular
glaucoma
progress
optic
neuropathi
character
function
structur
impair
ocular
tissu
includ
trabecular
meshwork
optic
nerv
head
retin
ganglion
cell
diseas
progress
caus
retin
ganglion
cell
death
lead
irrevers
blind
structur
chang
eye
tissu
lead
elev
intraocular
pressur
progress
apoptot
cell
death
glaucoma
singl
condit
heterogen
group
diseas
classifi
accord
age
onset
degre
ocular
hypertens
common
treatment
strategi
reduct
intraocular
pressur
topic
antiglaucoma
medic
howev
approach
caus
seriou
side
effect
may
fail
maintain
lower
intraocular
pressur
period
time
larg
number
patient
inhibit
aqueou
humor
secret
rnaibas
gene
therapeut
strategi
develop
specif
sirna
silenc
gene
express
trabecular
meshworkretina
caus
suppress
target
gene
eg
myocilin
express
might
increas
convent
outflow
decreas
aqueou
humor
flow
promot
neuroprotect
previou
studi
demonstr
topic
administr
specif
sirna
target
carbon
anhydras
gene
alpha
beta
adrenoceptor
lower
intraocular
pressur
rabbit
rate
compar
obtain
use
commerci
product
moreov
sirna
strategi
advantag
produc
longerlast
effect
compar
commerci
pharmaceut
product
mani
type
kerat
classifi
accord
caus
agent
frequent
form
diseas
one
relat
use
contact
len
caus
pseudomona
aeruginosa
symptom
rang
inflammatori
epitheli
edema
stroma
infiltr
lead
corneal
ulcer
stroma
tissu
destruct
vision
loss
sirna
employ
investig
role
two
import
defensin
ocular
immun
defens
system
murin
end
two
differ
mous
model
suscept
resist
balbc
p
aeruginosa
investig
knockdown
experi
reveal
host
resist
bacteri
infect
requir
defensin
modul
product
proinflammatori
cytokin
induc
synthas
ino
tlr
signal
molecul
nuclear
factor
kappa
b
activ
infect
cornea
thu
studi
demonstr
aforement
defensin
may
provid
promis
target
treatment
p
aeruginosa
kerat
brain
present
signific
challeng
biomed
scienc
notabl
lack
effect
therapi
disord
affect
organ
due
complex
great
divers
cell
type
varieti
function
need
understand
patholog
mechan
brain
disord
context
therapeut
base
rnai
could
help
understand
patholog
process
valid
diseas
target
vivo
investig
therapeut
potenti
target
gene
involv
neurolog
disord
effort
requir
understand
mechan
involv
abnorm
brain
function
improv
deliveri
method
interfer
technolog
cn
justifi
vast
number
diseas
affect
cn
neurolog
disord
consist
differ
diseas
affect
signific
portion
popul
given
life
expect
increas
occurr
diseas
like
increas
futur
cn
diseas
often
relat
mutat
may
result
abnorm
function
result
patholog
state
possibl
candid
rnai
respect
molecular
target
follow
intracrani
huntington
gene
parkinson
neurophat
neurodegen
diseas
includ
amyotroph
later
alzheim
ill
affect
hypoxicischem
event
brain
cjun
although
rnai
techniqu
promis
cn
still
challeng
region
deliv
rnaibas
formul
barrier
limit
entranc
molecul
restrict
passiv
entranc
materi
peripher
circul
brain
local
mucos
administr
sirna
via
endoscop
inject
treatment
diseas
affect
gastrointestin
tract
advantag
due
access
gastrointestin
mucosa
allow
releas
drug
directli
site
action
thu
reduc
side
effect
possibl
affect
nearbi
tissu
organ
beyond
therapeut
use
sirna
technolog
employ
import
tool
elucid
molecular
mechan
respons
variou
gastrointestin
diseas
discoveri
new
potenti
therapeut
target
inflammatori
bowel
diseas
ulcer
coliti
crohn
diseas
femal
reproduct
mucosa
main
site
entri
mani
pathogen
caus
infect
mainli
sexual
transmit
one
inflamm
neoplast
diseas
best
way
prevent
sexual
transmit
infect
topic
applic
therapeut
agent
advantag
use
low
dose
overlap
among
primari
site
infect
thu
use
topic
appli
microbicid
attract
prevent
treatment
method
nevertheless
one
main
disadvantag
topic
use
therapeut
agent
complianc
appli
immedi
sexual
intercours
thu
import
develop
therapeut
agent
effect
long
durat
one
applic
neutral
divers
viral
strain
agent
activ
rnai
pathway
deliv
sirna
target
specif
viral
bacteri
pathogen
studi
promis
microbicid
intravagin
sirna
could
provid
sustain
protect
viral
transmiss
overal
studi
pallis
et
al
wu
et
al
present
interest
approach
deliveri
sirna
vagin
mucosa
provid
excit
opportun
explor
use
topic
appli
sirna
treatment
sexual
transmit
infect
addit
recent
identif
sirna
target
cervic
cancer
human
immunodefici
viru
hiv
infect
infect
increas
interest
develop
vagin
deliveri
system
sirna
consensu
scientif
commun
sirna
emerg
one
promis
therapeut
strategi
sever
diseas
especi
genet
caus
describ
review
develop
use
differ
nanocarri
method
studi
deliveri
sirna
local
administr
import
find
discov
howev
maxim
potenti
sirna
therapeut
agent
strategi
allow
preferenti
deliveri
sirna
particular
tissu
cell
type
promot
action
target
cell
recent
develop
strategi
use
receptormedi
intern
seem
effect
mean
achiev
function
deliveri
sirna
main
pathway
intern
macromolecul
oligonucleotid
sirna
endocyt
pathway
subdivid
five
major
class
four
involv
cell
surfac
receptor
exampl
studi
conduct
goal
mind
use
hyaluron
acid
natur
linear
polysaccharid
present
skin
lung
intestin
extracellular
matrix
noteworthi
hyaluron
acid
induc
receptormedi
intracellular
signal
employ
differ
targetspecif
sirna
deliveri
system
increas
effect
promis
result
demonstr
combin
polysaccharid
differ
carrier
intracellular
deliveri
differ
sirna
facilit
hyaluron
acid
receptormedi
endocytosi
way
dramat
improv
sirna
deliveri
brain
obtain
combin
sirna
highdens
lipoprotein
hdl
allow
lipoprotein
endocytosi
similarli
sirna
deliv
immun
cell
receptormedi
endocytosi
either
encapsul
sirna
nanocarri
bear
target
antibodi
ligand
cell
surfac
receptor
complex
sirna
antibodi
fusion
protein
recent
publish
studi
propos
altern
approach
chimer
rna
compos
aptam
fuse
sirna
target
gene
knockdown
cell
bear
aptamerbind
receptor
aptamersirna
chimera
propos
prevent
hiv
sexual
transmiss
two
mechan
action
block
viral
entri
via
bind
rnai
knockdown
viral
gene
host
receptor
host
gene
requir
viral
replic
addit
strategi
overcom
biolog
barrier
administr
rout
topic
sirna
deliveri
understand
specif
mechan
intern
traffick
within
cell
nanocarri
mediat
sirna
deliveri
target
tissu
cell
guid
ration
develop
effici
nanocarri
deliv
sirna
allow
topic
treatment
mani
diseas
overal
studi
discuss
present
interest
approach
deliveri
sirna
provid
excit
opportun
use
topic
appli
sirna
treatment
wide
varieti
disord
local
deliveri
sirna
avoid
system
exposur
reduc
likelihood
unexpect
harm
effect
elsewher
bodi
result
drug
success
deliveri
system
exampl
either
vivo
clinic
studi
present
review
show
complex
formul
design
depend
sever
factor
includ
chemic
interact
sirna
formul
compon
technolog
process
obtain
deliveri
system
specif
sirna
strategi
overcom
differ
physiolog
barrier
topicalloc
administr
rout
peculiar
differ
local
administr
rout
allow
state
ideal
deliveri
system
sirna
howev
review
bring
inform
conduc
studi
ration
way
widespread
use
rnai
therapeut
diseas
prevent
treatment
depend
multidisciplinari
applic
pharmaceut
technolog
allow
construct
smart
multifunct
deliveri
system
along
elucid
new
molecular
target
sequencespecif
sirna
block
target
therefor
despit
remark
develop
made
area
last
decad
improv
local
sirna
applic
remain
signific
research
area
clearli
warrant
studi
